Incyte Corp.

As of October 17, 2025, Incyte Corp. is considered overvalued with a P/E ratio of 301 and an EV to EBITDA of 36.85, significantly higher than industry peers, despite a strong 1-year return of 31.82%.

As of July 30, 2025, Incyte Corp. shows a bullish technical trend supported by strong MACD and moving averages, despite mixed signals from Dow Theory and OBV, while outperforming the S&P 500 year-to-date and over the past year, but underperforming over three- and five-year periods.

As of June 30, 2025, Incyte Corp. is fairly valued with a P/E ratio of 301 and an EV to EBITDA of 36.85, reflecting its growth potential despite recent volatility and a decline in long-term performance compared to peers and the S&P 500.

As of June 3, 2025, the technical trend is mildly bullish, supported by weekly and monthly indicators, although daily moving averages suggest potential short-term weakness.

As of April 24, 2025, Incyte Corp. is considered undervalued with an attractive valuation grade, highlighted by a high P/E ratio of 301 and a strong ROCE of 16.27%, despite its recent stock performance lagging behind the S&P 500.

As of March 2022, Incyte Corp.'s management team includes Herve Hoppenot as Chairman, President, and CEO, with Julian Baker as Lead Independent Director and independent directors Jean-Jacques Bienaime, Paul Clancy, Wendy Dixon, and Jacqualyn Fouse.

Incyte Corporation is a biopharmaceutical company specializing in the discovery and development of therapeutics. As of March 2025, it reported net sales of $1.053 billion and a market cap of approximately $13.32 billion.

As of Jun 18, Incyte Corp. has a market capitalization of $13.32 billion, with net sales of $4.41 billion and a net profit of $21.27 million over the latest four quarters.